FDA Requests Additional Information Regarding Avastin Breast Cancer Application
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech says the agency is seeking additional information regarding progression-free survival.
You may also be interested in...
Genentech To Resubmit Avastin sBLA In Mid-2007
FDA is seeking substantially more information than expected from an NCI-sponsored trial for first-line treatment of metastatic breast cancer, the company says.
Genentech To Resubmit Avastin sBLA In Mid-2007
FDA is seeking substantially more information than expected from an NCI-sponsored trial for first-line treatment of metastatic breast cancer, the company says.
Roche Files Avastin EU Marketing Authorization Application For NSCLC
An sBLA for the oncologic in non-small cell lung cancer is already pending in the U.S.